Form 4: Tango Therapeutics Director John B. Ketchum Boosts Stake with RSU Grant and Stock Option Acquisition

Tango Therapeutics, Inc. Director John B. Ketchum has increased his beneficial ownership in the company through the acquisition of 6,250 restricted stock units and 37,500 stock options.

Summary

• John B. Ketchum, a Director of Tango Therapeutics, Inc. (TNGX), acquired 6,250 shares of common stock in the form of Restricted Stock Units (RSUs) on June 5, 2025.
• These RSUs will vest in their entirety on the earlier of June 5, 2026, or the date of the next annual meeting of stockholders, contingent on Mr. Ketchum's continuous service.
• Mr. Ketchum also acquired 37,500 stock options on June 5, 2025, with an exercise price of $3.51 per share.
• These stock options will vest in 12 substantially equal monthly installments over a one-year period, with the first vesting date on July 5, 2025, also subject to continuous service.
• The stock options have an expiration date of June 5, 2035.
• Following these transactions, Mr. Ketchum directly beneficially owns 20,937 shares of common stock and 37,500 stock options.
• The transactions were made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director is increasing their stake in the company through equity grants, signaling confidence and aligning interests with shareholders. This is a standard compensation event but still reflects insider commitment.

Positives

• The acquisition of additional equity by a director, John B. Ketchum, signals increased alignment of his interests with those of shareholders.
• The grant of RSUs and stock options provides long-term incentives for the director to contribute to the company's success and share price appreciation.
• The transactions were made under a Rule 10b5-1 plan, indicating a pre-arranged, non-discretionary acquisition.

Risks

• The value of the acquired RSUs and stock options is contingent on the company's future stock performance and the director's continuous service.
• The stock options' value is dependent on the stock price exceeding the exercise price of $3.51.

Future Outlook

The acquired RSUs are set to vest fully by June 5, 2026, or the next annual meeting, while the stock options will vest monthly over one year starting July 5, 2025, both contingent on the director's continued service.

Industry Context

This Form 4 filing reflects a standard equity compensation grant to a director, common practice in the biotechnology and pharmaceutical industry to align management incentives with long-term shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a common form of equity compensation in the biotechnology sector, similar to practices at companies like Moderna, BioNTech, or Regeneron, aiming to incentivize long-term commitment and performance.
• The vesting schedules (one year for options, one year or next annual meeting for RSUs) are typical for director compensation, providing a balance between immediate incentive and long-term retention, comparable to industry benchmarks for non-executive directors.

Stakeholder Impact

• Shareholders: The increased equity ownership by a director can be seen as a positive signal, potentially increasing confidence in the company's leadership and future performance, as their interests are more closely aligned.
• Employees: While not directly impacted, strong leadership alignment can indirectly benefit employees through stable company direction and potential growth.

Next Steps

• Continued service of John B. Ketchum with Tango Therapeutics, Inc. to ensure vesting of RSUs and stock options.
• Vesting of 37,500 stock options in 12 equal monthly installments starting July 5, 2025.
• Vesting of 6,250 RSUs on the earlier of June 5, 2026, or the next annual meeting of stockholders.

Key Dates

Keywords

Tango Therapeutics, TNGX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Grant, Beneficial Ownership